<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371692">
  <stage>Registered</stage>
  <submitdate>20/10/2016</submitdate>
  <approvaldate>4/11/2016</approvaldate>
  <actrnumber>ACTRN12616001523493</actrnumber>
  <trial_identification>
    <studytitle>Validating a new instrument for indirect calorimetry in the ICU: a comparison of gas exchange measurements between BEACON Caresystem and Deltatrac II. </studytitle>
    <scientifictitle>In mechanically ventilated adult ICU patients, how well does gas exchange measurement by a new device for indirect calorimetry (BEACON Caresystem) agree with the reference method (Deltatrac II)?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil. </secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critical illness</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Both study instruments will be connected in parallel, a mandatory 10 minute period is then provided before commencement of gas exchange measurements to allow the Deltatrac mixing chamber to equilibrate with expired gas from the patient after the initial break in the ventilator circuit during connection. A simultaneous measurement with Deltatrac II and BEACON Caresystem will then be performed. Average values for energy expenditure (EE), VO2, VCO2, minute ventilation (MV) and respiratory quotient (RQ) will be registered after a 20 minute period. Measurements where the reference method registers a mean RQ of &lt;0.6 or &gt;1.2 will be discarded.

All aspects of the patient's ICU therapy are determined by the attending physician. Changes in ventilator settings, disconnection of the ventilator circuit or patient mobilization are to be avoided during and one hour previous to measurements unless deemed necessary by medical staff. In such event the ongoing measurement will be discontinued and restarted after a 15 minute resting period. 

Patients can be measured on multiple occasions given a minimum interval of one calendar day. </interventions>
    <comparator>Energy expenditure as determined by the Deltatrac II is considered the reference method for statistical analysis when compared to the study instrument (BEACON Caresystem).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is the level of agreement between VO2 and VCO2 as determined by the study device (BEACON Caresystem) and the reference method (Deltatrac II).</outcome>
      <timepoint>Time of study measurements. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory quotient as determined by the study device (BEACON Caresystem) and reference method (Deltatrac II). </outcome>
      <timepoint>Time of study measurements. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Critically ill patients receiving invasive mechanical ventilation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Fraction of inspired oxygen concentration &gt;0.6, respiratory rate &gt;35, uncontrolled gas leaks in ventilatory circuit (chest drains, pneumothorax, bronchoesophageal fistula), leak in ventilator circuit &gt;10% of minute volume, ECMO/NO-therapy, absence of informed consent by patient or relative.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods>Limits of agreement and bias between VO2/VCO2 as measured by the study device (BEACON Caresystem) and reference method (Deltatrac II) will be compared using Bland-Altman plots. Agreement of energy expenditure values as measured by study device and the reference method will also be compared with the Bland-Altman method, although it is a dependent variable calculated from VO2 and VCO2. A sample size of 50 measurements in at least 20 patients is considered sufficient to determine limits of agreement within +/- 2.0 SD.

For descriptive statistics continuous variables will be analyzed for statistical significance using a two-tailed Student's t-test for paired samples and Wilcoxon signed-rank test as appropriate. An alpha level of =/&lt;0.05 is considered significant.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/11/2016</anticipatedstartdate>
    <actualstartdate>10/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <currentsamplesize>25</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Jan Wernerman</primarysponsorname>
    <primarysponsoraddress>Karolinska Institutet
Inst. for klinisk vetenskap, intervention och teknik
Enheten for anestesi
Karolinska Universitetssjukhuset, Huddinge, K32
141 86 Stockholm</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet</fundingname>
      <fundingaddress>Stockholm County Council
Stockholms lans landsting
Box 22550
104 22 Stockholm</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Mermaid Care A/S</othercollaboratorname>
      <othercollaboratoraddress>Hedelund 1
DK-9400 Nr. Sundby
Denmark</othercollaboratoraddress>
      <othercollaboratorcountry>Denmark</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Critical illness is characterized by a catabolic state and loss of lean body mass. It has been hypothesized that this process can be attenuated by nutritional therapies, but the optimal energy delivery for this heterogenous patient population remains unknown. Indirect calorimetry can accurately determine energy expenditure in individual patients, but previous studies (Sundstrom Rehal et al, Crit Care. 2016;20:54, Sundstrom et al, Clin Nutr. 2013 Feb;32(1), Graf et al Clin Nutr. 2014 Jan 21) have demonstrated varying agreement between instruments. Deltatrac II (Datex-Ohmeda, Helsinki, Finland) has historically been considered the gold standard for gas exchange measurements in intensive care but is no longer in production. 

The aim of this study is to determine the level of agreement of gas exchange measurements between two devices for indirect calorimetry in mechanically ventilated ICU patients: BEACON Caresystem (Mermaid Care, Nr. Sundby, Denmark) and Deltatrac II. We hypothesize that both instruments measure oxygen comsumption (VO2) and carbon dioxide production (VCO2) with equal precision and accuracy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Regionala etikprovningsnamnden i Stockholm</ethicname>
      <ethicaddress>Box 289 (Nobels vag 12 A)
171 77 Stockholm</ethicaddress>
      <ethicapprovaldate>26/10/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/09/2016</ethicsubmitdate>
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Jan Wernerman</name>
      <address>Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm</address>
      <phone>+46 8-58586395</phone>
      <fax />
      <email>jan.wernerman@karolinska.se</email>
      <country>Sweden</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Martin Sundstrom Rehal</name>
      <address>Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm</address>
      <phone>+46737164623</phone>
      <fax />
      <email>martin.sundstrom@gmail.com</email>
      <country>Sweden</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Martin Sundstrom Rehal</name>
      <address>Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm</address>
      <phone>+46737164623</phone>
      <fax />
      <email>martin.sundstrom@gmail.com</email>
      <country>Sweden</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Martin Sundstrom Rehal</name>
      <address>Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm</address>
      <phone>+46737164623</phone>
      <fax />
      <email>martin.sundstrom@gmail.com</email>
      <country>Sweden</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>